Provided by Tiger Trade Technology Pte. Ltd.

ADMA Biologics

9.25
+0.960011.58%
Post-market: 9.22-0.0294-0.32%19:59 EDT
Volume:22.37M
Turnover:211.18M
Market Cap:2.20B
PE:15.42
High:9.81
Open:9.47
Low:8.86
Close:8.29
52wk High:25.67
52wk Low:7.21
Shares:238.00M
Float Shares:233.86M
Volume Ratio:1.07
T/O Rate:9.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.6000
EPS(LYR):0.6000
ROE:35.56%
ROA:21.50%
PB:4.61
PE(LYR):15.42

Loading ...

ADMA Biologics Outlook FY Revenue USD 635 Million

THOMSON REUTERS
·
Feb 26

Corrected-ADMA Biologics Q4 Net Income USD 49.4 Million (Corrects Amount)

THOMSON REUTERS
·
Feb 26

ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

GlobeNewswire
·
Feb 18

ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares

Reuters
·
Feb 18

GUIDANCE: (ADMA) ADMA Biologics Expects 2026 Total Revenue About $635M, vs. FactSet Est of $631.9M

MT Newswires Live
·
Jan 12

ADMA Biologics posts FY 2025 revenue of USD 510 million and year-end cash of USD 88 million

Reuters
·
Jan 12

ADMA Biologics Inc - FY 2025 Preliminary Unaudited Total Revenue About $510-$511 Mln

THOMSON REUTERS
·
Jan 12

ADMA Biologics Inc - Expects FY 2026 Revenue $635 Mln, FY 2027 $775 Mln

THOMSON REUTERS
·
Jan 12

ADMA Biologics Announces Preliminary Full Year 2025 Unaudited Total Revenue and Provides Business Update

THOMSON REUTERS
·
Jan 12

ADMA Biologics Outlook FY Revenue USD 635 Million

THOMSON REUTERS
·
Jan 12

ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026

GlobeNewswire
·
Jan 05

The Bull Case For ADMA Biologics (ADMA) Could Change Following Its Higher 2025 Revenue Outlook Revision

Simply Wall St.
·
Dec 23, 2025

ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares

Reuters
·
Dec 17, 2025

ADMA Biologics (ADMA): Assessing Valuation as Short Interest Declines and Market Sentiment Improves

Simply Wall St.
·
Nov 27, 2025

High Growth Tech Stocks In The US For November 2025

Simply Wall St.
·
Nov 24, 2025

ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares

Reuters
·
Nov 22, 2025

ADMA Biologics (ADMA) Receives a New Rating from Cantor Fitzgerald

TIPRANKS
·
Nov 06, 2025

ADMA Biologics Reports Strong Q3 2025 Financial Results

TIPRANKS
·
Nov 06, 2025

Stock Track | ADMA Biologics Plunges 5.72% After-Hours Despite Strong Q3 Results and Raised Guidance

Stock Track
·
Nov 06, 2025

BRIEF-ADMA Biologics Q3 Revenue USD 134.2 Million

Reuters
·
Nov 06, 2025